Enteral Nutrition Company Luminoah Raises $25 Million Series B

CHARLOTTESVILLE, Virginia—Luminoah, a medical technology company focused on enteral nutrition, announced a $25 million Series B financing, saying the new capital will support expanded distribution of Luminoah Flow, the company’s cleared enteral feeding system, increased manufacturing capacity and continued development of its clinician-facing data platform.

The Series B includes $20 million in new equity capital and $5 million in previously issued convertible notes that converted as part of the financing. The financing was led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, Google Ventures, Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund and existing investors

Following clearance by the Food and Drug Administration in April 2026, Luminoah completed an early access program with patients in the Pacific Northwest and Southeast.

Neal Piper founded Luminoah after his son, Noah, depended on tube feeding during cancer treatment.

“For too long, families who depend on tube feeding have had to organize their lives around the pump. We built Luminoah so the technology could fit around their lives instead,” said Piper, founder and CEO of Luminoah. “Our family’s experience inspired a mission to make tube feeding simpler and give people greater freedom. With patients now using our technology and the support of exceptional investors, we’re ready to bring that vision to many more families.”

Luminoah Flow combines a pocket-sized, rechargeable feeding pump, nutrition pouches and a connected mobile app into one system. Patients can receive nutrition while moving through their day and track their feeding activity as the data uploads to the Luminoah mobile app. When patients choose to share their data, clinicians can review delivered nutrition through the Luminoah Intelligence data platform.

“Enteral nutrition has gone far too long without meaningful innovation. Luminoah is making nutrition therapy more portable, connected, and patient-centered while giving clinicians better information to guide care. That combination of clinical need, patient impact, and thoughtful innovation is exactly what we look for through the AGA GI Opportunity Fund,“ said Tom Serena, CEO of the American Gastroenterological Association.

Luminoah will use the new Series B capital to:

• Bring Luminoah Flow to more home medical equipment suppliers and health systems across the U.S.
• Expand production capacity and introduce automation for the Luminoah Flow system.
• Continue development of a clinician-facing data platform.